Nurix Therapeutics reported third‑quarter 2025 revenue of $13.6 million, a modest 2.4% increase from $13.3 million in the same period a year earlier. The company’s total revenue for the twelve months ended November 30, 2025 rose to $84.0 million from $54.5 million year‑over‑year, driven almost entirely by $30 million in license revenue from Sanofi extensions and $12 million in research milestone payments—$7 million from Sanofi and $5 million from Pfizer—underscoring the importance of partnership milestones to the company’s top‑line growth.
Operating expenses for the quarter reached $99.3 million, up from $67.2 million a year earlier, reflecting a significant increase in research and development costs as Nurix accelerates enrollment in its pivotal bexobrutideg program and prepares for the DAYBreak study. The company’s net loss for the quarter was reported, reflecting continued investment in clinical development and the associated cost structure of a late‑stage biopharmaceutical company.
Cash, cash equivalents and marketable securities stood at $592.9 million as of November 30, 2025, down slightly from $609.6 million a year earlier. The balance sheet supports roughly seven quarters of runway at current burn rates, giving the company a comfortable cushion to fund ongoing trials and operational needs while it seeks additional financing to sustain its growth trajectory.
The company announced the initiation of the DAYBreak registrational program for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia. Phase 1 data presented at the 2025 American Society of Hematology meeting showed an 83% objective response rate and a 22.1‑month progression‑free survival, providing strong early evidence of clinical efficacy. Nurix also reported continued progress in its IRAK4 degrader program with Gilead and its CBL‑B inhibitor program, NX‑1607, reinforcing the breadth of its degrader platform.
CEO Arthur T. Sands emphasized that the company is transitioning from early‑stage development to a late‑stage clinical focus, noting that the positive Phase 1 results and the launch of the DAYBreak program position Nurix to deliver degrader‑based medicines. He highlighted the company’s disciplined capital management and its commitment to investing in high‑potential assets while maintaining a robust cash position to support the next phase of its pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.